SRZN vs. APTO, BCLI, INKT, ZIVO, SABS, CRTX, AIM, PMCB, GMDA, and SNTI
Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), MiNK Therapeutics (INKT), ZIVO Bioscience (ZIVO), SAB Biotherapeutics (SABS), Cortexyme (CRTX), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Gamida Cell (GMDA), and Senti Biosciences (SNTI). These companies are all part of the "medical" sector.
Surrozen (NASDAQ:SRZN) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
66.6% of Surrozen shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 35.0% of Surrozen shares are held by insiders. Comparatively, 9.5% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aptose Biosciences has a consensus price target of $19.80, indicating a potential upside of 1,092.77%. Given Aptose Biosciences' higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Surrozen.
Surrozen has higher revenue and earnings than Aptose Biosciences. Surrozen is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Surrozen has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Aptose Biosciences received 371 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 65.85% of users gave Aptose Biosciences an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
Surrozen's return on equity of -55.24% beat Aptose Biosciences' return on equity.
In the previous week, Aptose Biosciences had 11 more articles in the media than Surrozen. MarketBeat recorded 13 mentions for Aptose Biosciences and 2 mentions for Surrozen. Surrozen's average media sentiment score of 0.44 beat Aptose Biosciences' score of 0.27 indicating that Surrozen is being referred to more favorably in the media.
Summary
Aptose Biosciences beats Surrozen on 8 of the 15 factors compared between the two stocks.
Get Surrozen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Surrozen Competitors List
Related Companies and Tools